Distinct alterations of fecal microbiota refer to the efficacy of adalimumab in Crohn’s disease
Background and Aims: Anti-tumor necrosis factor mAb (i.e., adalimumab, ADA) is currently used in the treatment of patients with Crohn’s disease (CD). However, its regulation on fecal microbiota is still not fully understood.Methods: A retrospective analysis was conducted on 115 patients with CD who...
保存先:
| 主要な著者: | , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2022-08-01
|
| シリーズ: | Frontiers in Pharmacology |
| 主題: | |
| オンライン･アクセス: | https://www.frontiersin.org/articles/10.3389/fphar.2022.913720/full |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|